These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6819080)

  • 1. Anti-tumor effects of an antiserum raised in syngeneic mice to a tumor-specific T suppressor factor.
    Maier T; Levy JG
    Cancer Immunol Immunother; 1982; 13(2):134-9. PubMed ID: 6819080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further characterization of thymic suppressor cells and a factor that suppress the generation of cells cytotoxic for a syngeneic tumor in DBA/2 mice.
    Levy JG; Maier T; Kilburn DG
    J Immunol; 1979 Mar; 122(3):766-71. PubMed ID: 109502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and characterization of a tumor-specific T suppressor factor from a T cell hybridoma.
    Steele JK; Stammers AT; Levy JG
    J Immunol; 1985 Apr; 134(4):2767-78. PubMed ID: 2579156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preadministration of a T-suppressor factor enhances tumor immunity in DBA/2 mice.
    Deal H; Steele JK; Stammers AT; Singhai R; Levy JG
    Cancer Immunol Immunother; 1989; 28(3):193-8. PubMed ID: 2493988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210.
    Steele JK; Singhai R; Stammers AT; Levy JG
    J Immunol; 1986 Nov; 137(9):3025-30. PubMed ID: 3489783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helper cells active in the generation of cytotoxicity to a syngeneic tumor.
    Hancock EJ; Kilburn DG; Levy JG
    J Immunol; 1981 Oct; 127(4):1394-7. PubMed ID: 6168688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of suppressor cells in mice bearing syngeneic mastocytoma.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1977 Feb; 118(2):412-7. PubMed ID: 65423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES; North RJ
    J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
    Baxevanis CN; Gritzapis AD; Spanakos G; Tsitsilonis OE; Papamichail M
    Cancer Immunol Immunother; 1995 Jun; 40(6):410-8. PubMed ID: 7543022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target.
    Al-Rammahy AK; Levy JG
    Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of a soluble factor that specifically suppresses the in vitro generation of cells cytotoxic for syngeneic tumor cells in mice.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1978 Apr; 120(4):1218-24. PubMed ID: 417138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a monoclonal antibody directed to a T cell suppressor factor.
    Maier T; Stammers AT; Levy JG
    J Immunol; 1983 Oct; 131(4):1843-8. PubMed ID: 6413579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
    Hines DL
    Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):861-5. PubMed ID: 4213016
    [No Abstract]   [Full Text] [Related]  

  • 17. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
    Gajewski TF
    J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
    Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W
    Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.